Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Net Income towards Common Stockholders came in at -$117.5 million in Q1 2026, up 41.97% YoY from -$82.8 million in Q1 2025, and down 8.68% on a QoQ basis from -$108.1 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$117.5 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 41.97% year-over-year to -$117.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$559.8 million (up 2.61% YoY) and the FY2025 annual result came in at -$644.8 million, down 39.06% from the prior year.
- Net Income towards Common Stockholders retreated to -$117.5 million in Q1 2026, from -$108.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$56.0 million in Q1 2022 to a low of -$202.5 million in Q1 2025.
- A 5-year average of -$106.3 million and a median of -$93.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders slumped 121.6% — and 2026, when it soared 41.97%.
- Tracing RXRX's Net Income towards Common Stockholders over 5 years: stood at -$68.0 million in 2022, then tumbled by 36.66% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then jumped by 39.56% to -$108.1 million in 2025, then slipped by 8.68% to -$117.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$117.5 million (Q1 2026), -$108.1 million (Q4 2025), and -$162.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | -131.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -131.01 Mn |
| Mar 31, 2026 | -117.50 Mn |
| Dec 31, 2025 | -108.12 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.49 Mn |
| Dec 31, 2024 | -178.91 Mn |
| Sep 30, 2024 | -95.84 Mn |
| Jun 30, 2024 | -97.54 Mn |
| Mar 31, 2024 | -91.37 Mn |
| Dec 31, 2023 | -93.00 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -68.05 Mn |
| Sep 30, 2022 | -62.59 Mn |
| Jun 30, 2022 | -66.21 Mn |
| Mar 31, 2022 | -56.00 Mn |
| Dec 31, 2021 | -64.98 Mn |
| Sep 30, 2021 | -46.62 Mn |